news
Lancet calls out research bias against pregnant people in Ebola trials
A new correspondence in The Lancet argues against the systematic exclusion of pregnant and breastfeeding people from clinical trials, specifically highlighting the ongoing Bundibugyo virus emergency. Historically, this exclusion aimed to protect fetuses and pregnant individuals, but authors note it often harms more than it helps by delaying access to effective treatments and vaccines for this vulnerable group.
A new correspondence in The Lancet argues against the systematic exclusion of pregnant and breastfeeding people from clinical trials, specifically highlighting the ongoing Bundibugyo virus emergency. Historically, this exclusion aimed to protect fetuses and pregnant individuals, but authors note it often harms more than it helps by delaying access to effective treatments and vaccines for this vulnerable group.
The architecture take
Here's a gut check moment: research on pregnant individuals often feels like it's stuck in the dark ages. The Lancet's call-out on Ebola trials isn't just about tropical diseases; it's a proxy for how we approach women's health research across the board. The 'protective' exclusion of pregnant and breastfeeding people from clinical trials means we lack critical data on drug efficacy and safety for a significant chunk of the population. This isn't just a missed opportunity; it actively puts lives at risk by forcing clinicians to make educated guesses instead of evidence-based decisions. It's a fundamental flaw in how we think about reproductive health within the broader medical architecture, and it's time for this 'protection' to evolve into true, informed care. What's required isn't blanket exclusion, but thoughtful inclusion that balances risk with access.